Hindustan Bio Sciences Ltd
₹
None%
- close price
About
Incorporated in 2000, Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Upcoming result date: 30 May 2025
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
3h - Annual Secretarial Compliance Report confirms full regulatory compliance for FY ended March 31, 2025.
-
Board Meeting Intimation for Considering The Audited Standalone Results For The Quarter And Financial Year Ended On March 31, 2025
19 May - Board meeting on May 30, 2025, to approve audited results and appoint auditors for 2025-30.
-
Announcement under Regulation 30 (LODR)-Change in Management
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
-
Appointment of Company Secretary and Compliance Officer
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday, April 23, 2025 - Appointment Of Mr. Devanshu Ravinder Dange As Company Secretary And Compliance Officer.
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
a) Tablets
b) Capsules
c) Eye/Ear/Nasal Drops
d) Dry and Liquid Injectables
e) Liquid/Dry Syrups
f) Pre-Filled Syringes
g) Non Sterile/Sterile Ointments